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2ABSTRACT
Sex Differences in Nicotine-conditioned Hyperactivity in a Model of Dopamine D2 Receptor 
Priming: Roles of Dopamine D2 and D3 Receptor Subtypes
by
Ashley Brianna Sheppard
The aim of this investigation was to determine the effect of a nicotine-conditioned context on 
locomotor hyperactivity in an animal model of D2-priming, and whether conditioned 
hyperactivity could be blocked by the D2 antagonist eticlopride or the D3 antagonist nafadotride. 
D2-primed male rats showed enhanced nicotine sensitization as evidenced by statistically 
significant differences in horizontal activity. D2-primed female rats administered nicotine 
demonstrated an increased hypoactive response after initial sensitization and increased 
stereotypy. Eticlopride and nafadotride blocked sensitization to nicotine in both D2-primed and 
non D2-primed males and females. Eticlopride blocked conditioned hyperactivity in females but 
not in males. D2-primed female rats administered nicotine demonstrated significantly higher 
conditioned-hyperactivity as compared to non D2-primed females and controls, and this increase 
was more effectively blocked by nafadotride as compared to eticlopride. These results suggest 
differential roles of the dopamine D2 and D3 receptors in both adolescent nicotine sensitization 
and conditioned activating effects of nicotine. 
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9CHAPTER 1
INTRODUCTION
Smoking is a convenient and legal form of drug self-administration that often begins in 
adolescence. Addiction to nicotine, the psychomotor stimulant drug found in cigarettes, often 
results (Benowitz, 1988; Faraday, Elliott, Phillips, & Grunberg, 2003; Jarvis, 2004). Nicotine has 
positive reinforcing effects that typically become associated with environmental and contextual 
cues (Bevins & Palmatier, 2003; Bevins, Eurek, & Besheer, 2004; Jarvis; Lazev, Herzog, & 
Brandon, 1999). After many pairings of smoking with a particular environment or within a 
specific context, the context in which the individual smokes appears to elicit strong cigarette 
cravings followed by smoking behavior (Bevins & Palmatier; Brandon, Piasecki, Quinn, & 
Baker as cited in Lazev et al., 1999; Jarvis). A rise in smoking-related health problems, 
evidenced by lung cancer surpassing breast cancer as the leading type of cancer in women in the 
United States, suggests that women in general are more sensitive to the effects of nicotine, have 
greater difficulty quitting, and use tobacco more frequently than men (Grunberg, Winders, & 
Wewers, 1991; Kandel, Warner, & Kessler as cited in Harrod et al., 2004; Waldron, 1991). 
The schizophrenic population in particular exhibits especially high rates of smoking 
which is nearly three times that of the general population (Kelly & McCreadle, 1999). According 
to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) (American Psychiatric Association, 2000), schizophrenia is a psychotic disorder in 
which patients experience symptoms such as delusions, hallucinations, disorganized speech, 
catatonic motor behavior, and negative affect. The disorder usually has an age of onset between
the late teens and mid-30s (American Psychiatric Association). Individuals suffering from 
schizophrenia exhibit impairments in many cognitive functions such as memory, attention, and 
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psychomotor abilities (American Psychiatric Association). The high incidence of smoking 
among these patients raises the possibility of an underlying neurochemical mechanism involving 
nicotine in which the midbrain dopaminergic system, also referred to as the mesocorticolimbic 
pathway, has been implicated (Dalack, Healy, & Meador-Woodruff, 1998). 
The Dopamine System
Dopamine, a catecholamine neurotransmitter that contains an amine group and a catechol 
ring, is synthesized from the amino acid tyrosine obtained from dietary protein (Kalat, 2004). 
Dopamine is a modulatory neurotransmitter that acts via two families of G-protein-coupled 
receptors that are divided into these two families based on similar pharmacological profiles 
towards dopamine agonists and antagonists (Cooper, Bloom, & Roth as cited in Kostrzewa, 
1995; Missale, Nash, Robinson, Jaber, & Caron, 1998). The dopamine D1-like receptor family 
consists of the D1 and D5 receptor types and the dopamine D2 -like receptor family consists of 
D2, D3 and D4 receptor types (Kostrzewa, 1995). Overactivity of the dopamine system has been 
implicated as playing a primary role in schizophrenia, obsessive-compulsive disorder (OCD), 
and bipolar disorder (Kostrzewa). Also, genetic polymorphisms of the D2 and D4 receptors have 
been reported in attention-deficit hyperactivity disorder (ADHD) (Bobb, Castellanos, Addington, 
& Rapoport, 2005). 
Behavioral changes resulting from the pharmacological induction of increases in 
dopaminergic activity in laboratory animals have been shown to produce symptoms similar to 
those observed in schizophrenic patients (Braff & Geyer, 1990). For example, studies from our 
laboratory have shown deficits in prepulse inhibition (PPI), a deficit commonly seen in 
schizophrenia (Adler, Freedman, Ross, Olincy, & Walso, 1998). This effect is hypothesized to 
result from increased dopamine D2 receptor supersensitivity as a consequence of neonatal 
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quinpirole treatment (Smith, Perna, & Brown, unpublished data). Interestingly, animal studies by 
Brown et al. (Brown & Kolb, 2001; Brown, Thompson, Thompson, Thacker, Ward, et al., 2004) 
have also shown that adulthood nicotine treatment can improve or alleviate cognitive deficits 
produced by neonatal quinpirole treatment. This suggests that schizophrenics may self-medicate 
through smoking in an attempt to assuage cognitive deficiencies produced by overactive 
dopamine function inherent to the disorder, although the mechanism through which nicotine 
works has yet to be delineated (Kumari & Postma, 2005).  
It has also been hypothesized that gliosis leading to a decrease in prefrontal dopamine 
activity subsequently results in an increase in dopamine D2 receptor sensitivity and 
mesocorticolimbic dopamine activity (Angelucci, Mathe, & Aloe, 2004; Davis, Kahn, Ko, & 
Davidson, 1991). Mesocorticolimbic dopamine neuron hyperactivity, coinciding with prefrontal 
dopamine hypoactivity, has been associated with cognitive deficits observed in schizophrenia 
(Davis et al.; Elvevag & Goldberg, 2000; Mackay et al., 1982). Additionally, increases in 
dopaminergic activity have been shown to depress cholinergic functioning, and cholinergic 
function has been shown to play a major role in cognition (Elvevag & Goldberg). Studies from 
our laboratory (Brown, Thompson, Thompson, Thacker, Ward, et al., 2004; Brown, Perna, 
Schaffer, & Williams, 2006) as well as Day and Fibiger (1992) have shown that activation of 
dopamine D2 receptors depresses acetylcholine function in the hippocampus and produces 
cognitive impairment. Thus, it appears that increases in dopaminergic function can result in 
changes that alter other neurotransmitter systems with behavioral consequences.
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Rodent Models of Schizophrenia
Rationale for Use of Animal Models
Animal models are valuable tools for studying aspects of diseases. Although there are 
limitations, such as the inability to study the long-term progression of a disease, animal models 
can be used as a means to elucidate underlying mechanisms and develop effective treatments for 
neurological disorders (Woodruff & Baisden, 1994). Another important aspect of animal models 
is that although it may be difficult to completely replicate a disorder in an animal, modeling even 
one aspect of that disorder can be very useful in discovering treatments. For example, 
Alzheimer's disease results in neurodegeneration of all neurotransmitter systems in the brain;
however, drug treatments designed to enhance cholinergic activity were discovered as the result, 
at least in part, on animal models of cognitive dysfunction (Yamada & Nabeshima, 2000). 
Relevant to this proposal, several rodent models of schizophrenia that used mesolimbic 
dopamine hyperactivity as the neural basis of the disease have proven useful in understanding 
behavioral and biochemical aspects of the disorder. 
Past Models of Schizophrenia: Dopamine Hyperactivity
Several past rodent models of schizophrenia have used acute administration of drugs such 
as apomorphine (Lacroix, Broersen, Feldon, & Weiner, 2000), amphetamine (Kokkinidis & 
Anisman, 1980), methamphetamine and cocaine (Yamamoto, 1997) that stimulate the dopamine 
system. A recently developed model of schizophrenia in which rats were administered 
amphetamine i.p. 3 days per week for 5 consecutive weeks has also been shown to create 
dopamine receptor supersensitivity as evidenced by amphetamine-induced locomotor activity 
and disruption in sensorimotor gating in animals tested using the PPI paradigm (Tenn, Fletcher, 
& Kapur, 2003; Tenn, Kapur, & Fletcher, 2005). Additionally, Lacroix et al. (2000) infused the 
13
indirect dopaminergic receptor agonist apomorphine into the prefrontal cortex which caused a 
disruption in prepulse inhibition, a behavioral manifestation of schizophrenia. Although these 
models have been beneficial in studying schizophrenia, acute administration of dopaminergic 
agonists does not represent the long-term dopamine dysfunction seen in schizophrenic patients. 
Other models have used acute administration of phencyclidine (PCP), an NMDA receptor 
antagonist, to mimic NMDA receptor hypofunction that is known to occur in schizophrenia 
(Heresco-Levy, Silipo, & Javitt, 1996; Millan, 2002, 2005). Noncompetitive blockade of NMDA 
receptors using PCP produces both positive and negative symptoms of schizophrenia in normal
subjects (Heresco-Levy et al.). Studies using this model have shown prepulse inhibition deficits 
and social withdrawal consistent with schizophrenia (Sams-Dodd, 1997). Additional studies have 
shown alleviation of both positive and negative symptoms of schizophrenia using NMDA 
agonists such as glycine and D-serine, suggesting NMDA receptors as targets for potential 
therapies (Heresco-Levy et al.). 
Lipska and Weinberger (2002) have developed a rodent model of schizophrenia through 
ablation of the ventral hippocampus in 7-day-old rats. The rationale for this model is based on 
known hippocampal neuropathology present in schizophrenia including decreased hippocampal 
volume and increased size of the lateral ventricles (Harrison & Eastwood, 2001). Findings from 
this model have shown reductions of dopamine transporter (DAT) mRNA in the VTA and 
substantia nigra in adult rats (Lipska, Lerman, Khaing, & Weinberger, 2003) as well as several 
behavioral deficits seen in schizophrenia including increased locomotor activity and cognitive 
impairments (Chambers, Moore, McEvoy, & Levin, 1996). This particular model is challenging 
due to unavoidable damage to cortical and some subcortical areas as a result of lesioning the 
hippocampus at the early age at which the procedure must be performed. Also, changes in 
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hippocampal synaptic connectivity, but not cell death, have been observed in schizophrenic 
patients postmortem, creating another weakness for this particular model (Harrison & 
Eastwood). 
Neonatal Quinpirole Model: A New Model of Schizophrenia
Quinpirole, a dopamine D2/D3 receptor agonist, administered to rats during the neonatal 
period has been shown to produce long-term dopamine D2 receptor supersensitivity, also known 
as 'D2 receptor priming'(Kostrzewa, 1995; Kostrzewa & Brus, 1991; Kostrzewa, Hamdi, & 
Kostrzewa, 1990). Priming of the D2 receptor refers to increased physiological, biochemical, or 
behavioral responses of dopamine D2 receptors to dopamine agonists and is thought to account 
for altered drug-induced behavioral responses in several neurological disorders including 
schizophrenia, bipolar disorder, and attention-deficit hyperactivity disorder (ADHD) (Bobb,
Castellanos, Addington, & Rapoport, 2005; Kostrzewa; Rosa-Neto et al., 2005; Versiani, 2006). 
Dopamine D2 receptor priming has been shown to alter overall brain function through influences 
on other neurotransmitter systems, including the acetylcholinergic system (Brown et al., 2004; 
Brown, Perna, Schaefer, & Williams, 2006). 
Similarities have been observed between the neonatal quinpirole model of schizophrenia 
and data from the human schizophrenia literature. For example, amphetamine administration to 
adult rats neonatally treated with quinpirole produce a robust increase in dopamine release in the 
striatum (Nowak, Brus, & Kostrzewa, 2001). Studies using magnetic resonance imaging (MRI) 
and positron emission tomography (SPECT) imaging have shown that amphetamine 
administration also produces a large increase in dopamine release in the striatum of 
schizophrenics (Lavalaye et al., 2001; Soares & Innis, 1999). 
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Secondly, neonatal quinpirole treatments have been shown to produce deficits in auditory 
sensorimotor gating using prepulse inhibition (PPI). PPI of the startle response refers to 
attenuation in response to a strong stimulus (pulse) if this is preceded shortly by a weak non-
startling stimulus (prepulse). PPI provides a simple operational measure of sensorimotor gating 
that is often disrupted in schizophrenia (Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001; 
Kumari & Sharma, 2002). Our laboratory has shown that adult rats that received neonatal 
quinpirole treatment demonstrated PPI deficits as compared to controls using different prepulse 
auditory intensities (73, 76, and 82 dB) and different intervals between the prepulse and pulse 
(50, 100, and 150ms) (Maple, unpublished data).   
Third, neonatal quinpirole treatments have been shown to produce long-term cognitive 
impairment (Brown, Gass, & Kostrzewa, 2002; Brown, Thompson, Thompson, Thacker, Ward, 
et al., 2004). It has been well-documented that severe cognitive impairments are present in 
schizophrenia, and it has been suggested that cognitive impairment is a core feature of the 
disorder (Adler et al., 1998; Adler, Freedman, Ross, Olincy, & Walso, 1999; Elvevag & 
Goldberg, 2000). Cognitive deficits have also been hypothesized to be associated with 
sensorimotor gating in schizophrenics (Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001).
Fourth, our laboratory has very recently shown that chronic treatment with the atypical 
antipsychotic olanzapine, or Zyprexa, given twice daily in adulthood alleviated cognitive deficits 
produced by neonatal quinpirole treatment (Thacker et al., 2006). Importantly, this treatment also 
alleviated the significant increase in yawning produced by rats neonatally treated with quinpirole 
to control levels, essentially reversing the D2-priming effect. These data demonstrate that not 
only is D2-priming likely primarily responsible for these behavioral effects, but that 
antipsychotic treatments are effective in alleviating these effects. Additionally, in vitro analyses 
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showed that significant decreases in nerve growth factor (NGF) in the hippocampus produced by 
neonatal quinpirole were reversed by olanzapine in brain tissue that was not taken until after an 
8-day olanzapine washout (Thacker et al.).  However, expression of proteins was affected only in 
the hippocampus and not in areas known to be important in cognitive functioning suggesting a 
different mechanism for apparent alleviation of cognitive deficits in the Morris Water Maze task 
(Brown, Perna, Maple, Wilson, & Miller, 2008).  
Fifth, neonatal quinpirole treatments have been shown to alter overall brain function 
through influences on other neurotransmitter systems, including the acetylcholinergic system, 
(Brown et al., 2004; Brown, Perna, Schaefer, & Williams, 2006) and produce neurochemical 
abnormalities in adulthood that are similar to observations made in human schizophrenics. 
Results from this laboratory have shown that neonatal quinpirole treatment produced a 36% 
decrease in choline acetyltransferase (ChAT) and a significant decrease in nerve growth factor 
(NGF) expression in the hippocampus compared to saline controls in both early postweanling 
and adult rats (Brown et al., 2004; Brown, Thompson, Click, Thacker, & Perna, 2005; Brown, 
Perna, Maple, Wilson, & Miller, 2008). Research in non-medicated human schizophrenics have 
demonstrated a decrease in overall NGF expression, which has been suggested to account for 
neurodevelopmental abnormalities seen in schizophrenia (Aloe, Iannitelli, Angelucci, Bersani, & 
Fiore, 2000; Parikh, Evans, Kahn, & Mahadik, 2003). 
Finally, PCR analyses from our laboratory have shown a significant decrease in the 
genetic expression of alpha7 nicotinic receptors in the hippocampus of D2-primed animals 
(Brown et al., unpublished data). Reduced alpha7 expression is consistent with studies in human 
schizophrenic patients that have shown a reduction in availability in the alpha7 nicotinic receptor 
subunit gene (Leonard et al., 2002). Recently our lab has also shown decreases in RGS-9 protein 
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expression (Maple, Perna, Parlaman, Stanwood, & Brown, 2007) in agreement with Seeman et 
al. (2007) who have shown reductions in RGS9-2 mRNA expression in hippocampus tissue of 
schizophrenics.  
Therefore, it appears there are several similarities between the D2 receptor priming 
model and schizophrenia, and this model may be valid for the study of this disorder. However, 
further investigation of the effects of D2 priming on the serotinergic system, and the presence of 
NMDA receptor hypofunction is required in order to further validate the neonatal quinpirole 
model of schizophrenia.
Behavioral Sensitization
Behavioral sensitization is defined as an increase in behavioral response to repeated 
presentations of a stimulus (Kelley & Rowan, 2004; Wise & Bozarth, 1987). Locomotor activity 
is defined as horizontal movement and vertical rearing and is thought to result from activation of 
mesolimbic dopamine projections from the ventral tegmentum to the nucleus accumbens during 
psychomotor drug stimulation of the reward pathway, although other neurotransmitters are 
undoubtedly involved as well (Clarke, Fu, Jakubovic, & Fibiger, 1988; Kalivas & Stewart, 1991; 
Wise & Bozarth). Several drugs in the psychostimulant class, including amphetamine, cocaine, 
and nicotine, have been shown to increase dopamine function and also produce locomotor 
sensitization (Booze, Welch, Wood, Billings, Apple, & Mactutus, 1999; Chiang, Chen, & Chen, 
2003; Kosowski & Liljequist, 2005; Kuczenski & Segal, 2001; Perna, in press; Segal & 
Kuczenski, 1992; Tenn, Kapur, & Fletcher, 2005). Additionally, blockade of dopamine D1 and 
D2 receptors through pretreatment with a D1 or D2 antagonist such as SCH 23390 or eticlopride 
have been shown to block sensitization to psychostimulants (Schindler & Carmona, 2002).
Further, ablation of areas rich in dopaminergic cell bodies in the ventral tegmental area or 
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dopaminergic terminals in the nucleus accumbens has also been shown to be effective in 
blocking locomotor sensitization to psychostimulant drugs (Clarke et al., 1988).  Thus, it appears 
that the dopamine system plays a crucial role in locomotor sensitization to psychostimulants.
Anatomy of the Nucleus Accumbens 
The primary brain pathway involved in drug addiction appears to be the 
mesocorticolimbic pathway that  originates from dopaminergic cell bodies in the ventral 
tegmental area (VTA) of the midbrain and projects to the nucleus accumbens (NAcc), amygdala, 
hippocampus, bed nucleus of the stria terminalis, and prefrontal cortex (Kumari & Postman, 
2005; Vetulani, 2001).The nucleus accumbens has been shown to be the center of primary drug 
reward in the brain and has been histologically defined in two parts: the core and the shell. Based 
on histological analysis, the shell of the nucleus accumbens (AccSh) has been proposed to be an 
extension of the amygdala, the emotional center of the brain that is thought to play an important 
role in associative learning, particularly in situations involving rewarding and emotional 
behaviors (Everitt, Morris, O’Brien, & Robbins, 1991; Meredith, Callen, & Scheuer, 2002). The 
core sends projections to the substantia nigra and other areas associated with motor function such 
as the putamen, caudate, globus pallidus, as well as the frontal cortex (Balfour, Wright, Benwell,
& Birrell, 2000; Mogenson & Yang, 1991). Increased dopamine transmission in the nucleus 
accumbens shell during or immediately after drug administration is thought to account for the 
reinforcing properties of drug use that facilitates addiction by consolidating associative learning 
neural traces via D1 receptors (Di Chiara et al., 2004).
Role of the Nucleus Accumbens in Behavioral Sensitization
Increased locomotor activity after treatment with psychostimulants has been shown to 
result from stimulation of dopaminergic neurons located in the nucleus accumbens core (Balfour 
19
et al., 2000; Imperato & Di Chiara as cited in Joseph, Datla, & Young, 2003; Pontieri, Tanda, 
Orzi, & Di Chiara, 1996). According to the psychomotor theory of drug addiction proposed by 
Wise and Bozarth (1987), locomotor activity can be used to predict the reinforcing effects and 
addictive liability of drugs because both effects stem from a common mechanism involving the 
nucleus accumbens that is also responsible for reinforcement associated with natural rewards 
such as food and water. Natural rewards stimulate aversive centers through a feedback 
mechanism in order to control reward-seeking behaviors. However, artificial chemical rewards 
such as drugs of abuse stimulate the reward pathway but are not restrained by the controlling 
feedback mechanism possibly producing addiction (Vetulani, 2001). 
Drugs in the psychostimulant class, including nicotine, have been shown to have strong 
associative properties that likely make them susceptible to addiction. For example, Pontieri et al. 
(1996) used microdialysis, a technique for collecting neurotransmitter samples by perfusion of 
artificial cerebrospinal fluid through a particular brain region using a specialized probe (Joseph 
et al., 2003), to show dose-dependent increases in dopamine transmission in the nucleus 
accumbens of rodents that were administered intravenous (i.v.) nicotine. Nicotine was 
administered via an i.v. pulse in an attempt to approximate the pharmacokinetics of inhaled 
nicotine from tobacco smoke. Pontieri et al. suggest that positive motivational states induced by
NAcc dopamine transmission may facilitate the association of contextual stimuli with the 
psychostimulant effects of nicotine to acquire incentive properties through the process of 
motivational learning. 
Studies have shown an increase in dopamine release over subsequent administration of a 
range of psychostimulants including amphetamine, cocaine, and methamphetamine (Akimoto, 
Hamamura, Kazahaya, Akiyama, & Otsuki, 1990; Kalivas & Duffy, 1990; 1993; Wolf, White, 
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Nassar, Brooderson, & Khansa, 1993). Behavioral sensitization is thought to result from this 
increased dopamine release by neurons located in the VTA which creates dopamine overflow in 
the nucleus accumbens core (Kalivas & Stewart, 1991). The NAcc core sends retroactive 
projections to the midbrain motor centers, including substantia nigra, medial subthalamic 
nucleus, and pedunculopotine motor region, resulting in increased locomotor activity (Pierce & 
Kalivas, 1997). 
Involvement of Dopamine Receptors in Nicotine Sensitization
 It has been suggested that decreased inhibition of neurons controlled by presynaptic 
dopamine D3 autoreceptors or increased postsynaptic D1 or D2 receptor sensitivity to dopamine 
in the nucleus accumbens and striatum may play a role in the development of behavioral 
sensitization and are associated with the processes underlying addiction (Balfour et al., 2000; 
Chiang, Chen, & Chen, 2003; Le Foll, Diaz, & Sokoloff, 2003). Behavioral sensitization induced 
by psychostimulant drugs such as nicotine may specifically reflect stimulation of dopamine 
receptors within the core of the nucleus accumbens. However, results from a study by Le Foll, 
Diaz, et al. (2003) showed increases in dopamine D3 receptor binding and mRNA expression in 
the nucleus accumbens shell, but not core, after subchronic nicotine administration. In addition to 
increased D3 receptor expression, studies have shown increases in dopamine transporters in 
response to repeated nicotine administration (Harrod et al., 2004). Interestingly, studies to date 
have failed to demonstrate changes in D1 or D2 receptor expression or sensitivity after repeated 
nicotine administration (Harrod et al.; Le Foll, Diaz, et al.). 
Dopamine D3 receptors have been shown to have greater occupancy for dopamine as 
compared to D1 and D2 receptor subtypes (Richtand, Goldsmith, Nolan, & Berger, 2001). It has 
been hypothesized that locomotor activity in rodents is mediated by the opposing actions of 
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D1/D2 receptor activation and D3 receptor inhibition, and that rapid D3 receptor tolerance due to 
increased affinity for dopamine and D3 receptor down-regulation after chronic psychostimulant 
administration leads to observed increases in locomotor activity (Richtand, Goldsmith, Nolan, & 
Berger, 2001; Richtand et al., 2000). D3 receptor antagonism has been shown to block 
sensitization to amphetamine (Chiang, Chen, & Chen, 2003; Richtand et al., 2000) providing 
support for this hypothesis. However, Filip, Papla, and Czepeil (2002) observed increases in the 
expression of sensitization to cocaine after administration of the D3 receptor antagonist 
nafadotride on the 10th day of drug administration. Another study showed that although 
sensitization was observed, there were no significant differences in locomotor activity between 
wildtype and D3-receptor knockout mice after repeated cocaine administration, suggesting that 
D3-receptors do not play an important role in the expression of behavioral sensitization 
(Betancur et al., 2001). These results may reflect species-specific neurochemical differences 
between rats and mice or the development of a compensatory mechanism of D3 receptor 
deficient mice to expression of sensitization. Therefore, involvement of the D3 receptor in 
sensitization to different psychostimulants warrants further investigation in both species.
In a study by Le Foll, Schwartz, and Sokoloff (2003), D3 antagonism blocked the 
conditioning effects of nicotine in rats that had nicotine repeatedly paired with a particular 
environment. In another study utilizing the conditioned-place preference paradigm, Le Foll, 
Sokoloff, Stark, and Goldberg (2005) showed that the selective D3 receptor antagonist ST 198 
blocked the expression of nicotine-conditioned place preference without affecting locomotor 
activity (Le Foll, Sokoloff, et al.). These results suggest that D3 receptors are selectively 
involved in the associative effects of nicotine but may not play a role in the locomotor activating 
effects of the drug (Le Foll, Schwartz, et al.; Le Foll, Sokoloff, et al.). 
22
The expression of D3 receptors and behavioral sensitization is thought to result from 
changes in striatal and accumbal connectivity by repeated nicotine-administration triggered 
release of brain-derived neurotrophic factor (BDNF) originating from cortico-striatal neurons 
(Guillin et al., 2001; Le Foll, Diaz, et al., 2003). Guillin et al. (2001) have suggested that 
repeated use of addictive drugs alters BDNF expression that subsequently influences dopamine 
responsiveness in areas associated with environmental cues and context, such as the amygdala, 
inducing drug-conditioned responses to contextual stimuli. In line with this hypothesis, LeFoll, 
Diaz, et al. have also shown increased D3 receptor expression in the nucleus accumbens after 
repeated conditioning of nicotine to an environmental context. Additional studies are needed to 
determine the role of D3 receptors and their interaction with BDNF in drug addiction.
Involvement of Non-Dopaminergic Systems in Nicotine Sensitization
Balfour et al. (2000) suggest that projections in the shell of the nucleus accumbens
exhibit burst firing that is dependent upon N-methyl-D-aspartate (NMDA) receptor stimulation 
by acute nicotine administration and is important for the initiation of behavioral sensitization. 
However, chronic nicotine administration is required to stimulate burst firing in core projections. 
Support for this hypothesis was demonstrated in several recent studies. Results from these 
studies showed that NMDA receptor antagonists inhibited nucleus accumbens core dopamine 
overflow in sensitized animals that were pretreated with nicotine. This group did not show 
significant changes in the augmented locomotor response, suggesting a major role of post 
synaptic dopamine receptors in the mediation of nicotine sensitization (Balfour, Birrell, Moran, 
& Benwell, 1996; Birrell & Balfour, 1998; Shoaib, Benwell, Akbar, Stolerman, & Balfour, 1994; 
Suemaru, Gomita, Furunu, & Araki, 1993). 
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Nicotine Conditioned Hyperactivity
Behavioral sensitization can be achieved by using classical Pavlovian conditioning in 
which a previously neutral stimulus, such as a particular environment, can acquire rewarding 
properties through learned association. This occurs when a biologically rewarding stimulus, such 
as nicotine, is temporally paired with an environmental context. Drug-associated conditioned 
stimuli may also acquire the ability to elicit responses related to cravings, withdrawal, and drug 
seeking behavior (Robinson, & Berridge, 1993; Siegel as cited in Bevins & Palmatier, 2003). 
Bevins and Palmatier (2003) used a locomotor conditioning paradigm in which nicotine 
was repeatedly administered and reliably paired with a locomotor arena every day for a total of 8 
conditioning days. Contextual conditioning was followed by a drug-free trial in which animals 
were given a saline injection and placed into the same locomotor arena that had been reliably 
paired with nicotine. Results from this study showed significant increases in locomotor activity 
in drug-context paired groups as compared to saline-context paired groups during the 
postconditioning drug-free test, demonstrating the ability of an environmental context stimulus to 
evoke nicotine-conditioned hyperactivity. 
Nicotine conditioning to a particular context elicits locomotor hyperactivity that has been 
hypothesized to result from positive reinforcement and, in theory, should also elicit increased 
dopamine release. Although a significant increase in activity could result from other changes 
produced by the drug, such as nicotine-induced nicotinic receptor upregulation, studies have 
shown that dopamine may play an important role in nicotine conditioned hyperactivity. This 
hypothesis is supported by the ability of D2 antagonists such as haloperidol to interfere with 
conditioned stimulus control of sensitization (Kalivas & Stewart, 1991) and the ability of the 
selective D3 antagonist SB-277011A to decrease nicotine-induced conditioned locomotor 
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activity in rats (Pak et al., 2006). Bevins, Besheer, and Pickett (2001) have shown that 
administration of the selective D1 antagonist SCH-23390 during the post nicotine drug-free trial 
prevented the expression of a context-nicotine association. In a subsequent study, administration 
of SCH-23390 during the conditioning phase did not affect the acquisition of a nicotine-
environment association suggesting a greater role of the D1 receptor in the expression, as 
opposed to acquisition, of conditioned hyperactive behavior induced by nicotine (Bevins et al.).
Increases in nucleus accumbens dopamine release during drug-free testing would suggest 
that schizophrenic patients may experience greater drug reinforcement when exposed to drug-
associated cues than a normal individual due to further activity in an already hyperactive 
dopaminergic system. Whether this increased locomotor activity is a product of an 
overabundance of dopamine or reflects an increase in dopamine receptor sensitivity is yet to be 
determined. Although dopamine appears to play an important role, the roles of other 
neurotransmitter systems should also be evaluated.
Age Differences in the Effects of Nicotine on Behavior
Individuals who begin smoking at an early age have increased difficulty quitting as adults 
(Jarvis, 2006). Faraday et al. (2003) suggest that this is due to differences in acute and long-term 
effects of nicotine. Studies have shown that both male and female adolescent rats exposed to 
nicotine demonstrated increased activity compared to saline control animals without drug 
administration, whereas adult rats administered the same doses showed activity levels 
comparable to saline-controls (Elliot, Faraday, Phillips, & Grunberg, 2005; Faraday, Elliot, 
Phillips, & Grunberg, 2003). Adolescent rats also showed less sensitivity to nicotine’s initial 
hypoactivity effects and adolescents that were initially exposed to nicotine demonstrated an 
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overall increase in activity when reexposed to the drug as adults suggesting that early exposure 
may alter adulthood response to nicotine (Elliot et al.; Faraday et al.).
In a recent study from our laboratory, dopamine D2-primed adolescent rats demonstrated 
a more robust sensitization to nicotine as compared to adult rats (Perna, under review). Nicotine 
sensitization was more robust in female subjects neonatally treated with saline as compared to 
male subjects that received the same neonatal treatment. This is consistent with past findings by 
Booze et al. (Booze et al., 1999; Harrod et al., 2004). 
There are several possible mechanisms for age differences in reactions to nicotine. It has 
been hypothesized that there may be different rates of metabolizing nicotine between adults and 
adolescents (Faraday et al., 2003). However, there have been no significant differences in 
nicotine metabolism mediated by CYP2A-6, an enzyme important for the clearance of nicotine, 
in adolescents as compared to adults (Hukkanen, Jacob, & Benowitz, 2005). Lapin et al. (1987) 
also failed to find sustained changes in metabolism after both acute and sustained nicotine 
exposure. Additionally, age differences in nicotinic acetylcholine receptor distribution, density, 
and affinity may also partly account for age differences in nicotine reactivity based on the 
regulation of both decreased and increased activity by central nicotinic cholinergic systems (Di 
Chiara as cited in Faraday et al., 2003; Stolerman, Garcha, & Mirza, 1995) Faraday et al. (2003) 
suggest that a difference in nicotinic receptor subpopulations may exist with lower doses 
activating the activity-decreasing subpopulation to a lesser extent in adolescents as compared to 
adult rats. 
Rate differences in receptor up-regulation and desensitization in response to drug 
administration have been observed as adolescent D3 receptor levels at only 40% of adult levels 
(Faraday et al. 2003; Shram, Funk, Li, & Le, 2006). Although speculative, this suggests 
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schizophrenic patients who begin smoking during adolescence may have a more difficult time 
quitting due to the decrease in negative responding to initial nicotine exposure possibly resulting 
from decreased prevalence of the D3 receptors coupled with the potential cognitive deficit 
alleviating capacity of nicotine. Differences in the rates of receptor up-regulation and 
desensitization in response to nicotine administration may be especially important when 
examining nicotine addiction in schizophrenia due to dopamine receptor dysfunction thought to 
underlie the disorder. 
Sex Differences in the Effects of Nicotine on Behavior
 Although no sex differences in the initial response to nicotine have been reported, female 
rats exhibit increased locomotor activity, greater sensitivity to lower doses, as well as an 
increased number of the dopamine transporter (DAT) in both the shell and core of the NAcc after 
chronic nicotine administration as compared to males (Booze et al., 1999; Elliot et al., 2005; 
Faraday et al., 2003; Harrod et al., 2004; Kanyt, Stolerman, Chandler, Saigusa, & Pogun, 1999; 
Perna, manuscript in preparation). Studies have shown increased levels of dopamine transporter 
in female rats as compared to males resulting in increased synaptic availability of dopamine that
may account for, in part, for sex differences in locomotor activity (Booze et al., 1999; Harrod et 
al., 2004). Studies have also shown that female rats do not exhibit hyperactive effects in the 
absence of nicotine seen in males given the same doses (Elliot et al.; Faraday et al.). Sex 
differences in dopamine D1 and D2 receptor sensitivity in response to both agonists and 
antagonists after psychostimulant administration suggests that both receptors are important in the 
locomotor activating effects observed in behavioral sensitization (Frantz & Van Hartesveldt, 
1999; Schindler & Carmona, 2002). Differential expression of D3 receptors may also partially 
explain sex differences in locomotor activity levels. It is possible that female rats exhibit higher 
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activity levels due to a decrease in D3-regulated inhibition of activity. This hypothesis is 
supported by autoradiography studies that have shown decreased numbers of D3 receptors in the 
NAcc in female rats as compared to males after repeated intravenous nicotine administration 
(Harrod et al., 2004). 
Schindler and Carmona (2002) found a significant antagonistic effect of SCH 23390 and 
increased locomotor activating effects of the dopamine uptake inhibitor GBR 12909 and the D1 
agonist SKF 92958 in female rats as compared to males after cocaine administration. These 
results suggest increased dopamine D1 receptor sensitivity in females. The authors also found 
that male rats were more sensitive to the activity depressing effects of quinpirole suggesting that 
D2 receptor function may possibly account for the lower activity of males as compared to female 
rats after psychostimulant drug administration (Schindler & Carmona). 
Studies from this laboratory (Brown, Thompson, Click, Best, Thacker, & Perna, 2005;
Brown, Perna, Schaefer, & Williams, 2006) have shown a three-fold increase in yawning, a D2-
mediated behavior, and deficits on a match-to-place Morris Water Task (MWT) in males 
neonatally treated with quinpirole as compared to female rats suggesting further sex differences 
in dopamine receptor sensitivity. Acute administration of the dopamine D2 antagonist eticlopride 
before place-version MWT training to animals neonatally treated with saline produced deficits in 
both male and female rats with males also showing deficits in a match-to-place MWT suggesting 
a greater importance of the D2 receptor in cognitive performance in male versus female rats 
(Brown, Thompson, et al.; Brown, Perna, et al.). 
It is possible that sex differences observed in behavioral sensitization may be due to sex 
differences in nicotine distribution, metabolism, (Kyerematen, Owens, Chattopadhyay, 
deBethizy, & Vesell, 1988) and pharmokinetics as evidenced by higher nicotine arterial plasma 
28
levels in female rats chronically administered nicotine (Harrod, Booze, & Mactutus, 2007). It is 
thought that sex-dependent differences observed in behavioral sensitization result in part from 
modulation of striatal dopamine release by gonadal hormones (Booze et al., 1999; Dluzen & 
Anderson, 1997; Harrod et al., 2004; Kanyt et al., 1999). Becker (1999) has shown that estrogen 
down-regulates dopamine D2 autoreceptors and causes decreased firing of projections that 
synapse on gamma-aminobutyric acid (GABA) –B receptor subtypes found on dopamine 
receptor terminals resulting in enhanced striatal dopamine release. This enhancement of 
dopamine release is thought to result in enhanced behavioral responses including locomotor 
hyperactivity as a result of amphetamine stimulation, sensorimotor efficiency, and pacing during 
sexual behavior (Becker, 1999). Dluzen and Anderson (1997) reported greater dopamine output 
in tissue from castrated females treated with estrogen as compared to both male rats and female 
castrated animals not treated with estrogen. The authors also showed a decrease in striatal 
dopamine release in castrated males treated with estrogen demonstrating sex-dependent 
bidirectional effects of estrogen (Dluzen & Anderson). 
 Studies have shown estrous cycle-dependent increases in amphetamine-induced release 
of striatal dopamine as well as influences on sensorimotor functions and stereotypic behavior 
(Becker & Cha, 1989; Becker, Snyder, Miller, Westgate, & Jenuwine, 1987). Estrous cycle 
effects were not observed in nicotine self-administration behavior nor did estrogen appear to 
have a significant effect on nicotine-induced locomotor hyperactivity in female rats (Donny et 
al., 2000; Kuo et al., 1999). However, Franklin et al. (2004) have demonstrated significantly less 
cue-induced cravings in women in the follicular phase of the estrous cycle as compared to 
women in luteal phase or men suggesting an influence of sex hormones in response to nicotine or 
at least in response to nicotine-associated cues. Further studies are needed to determine the 
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extent, if any, that estrous cycle hormones affect behavioral responses to nicotine and nicotine-
associated cues and whether these responses are altered by dopamine D2 receptor 
supersensitivity.
Research Questions Addressed in this Thesis
The aim of this study was to examine the following: 
1) Analyze the effects of the dopamine D2 and D3 receptor subtype antagonists 
eticlopride and nafadotride, respectively, on the ability of a nicotine-conditioned context to 
elicit locomotor activity in D2-primed and non-D2-primed adolescent rats. It was expected 
that the D2 antagonist eticlopride (Bevins & Palmatier, 2002), but not the D3 antagonist 
nafadotride, would block induction of nicotine sensitization. This prediction was guided by 
Murray and Bevins (2007) who reported that relatively high doses of nafadotride are required to 
inhibit locomotor activity and that this inhibition is probably the result of loss of D3 receptor 
selectivity.  However, based on the findings that nafadotride blocks the association of nicotine to 
the locomotor arena, it was expected that nafadotride, but not eticlopride, would block nicotine-
conditioned hyperactivity during the drug-free trial (Bevins & Palmatier; Le Foll, Diaz, et al.,
2003; Le Foll, Schwartz, et al., 2003).
2) Compare nicotine-conditioned hyperactivity and locomotor sensitization in D2-
primed and non-D2- primed adolescent rats. A nicotine-conditioned environment was 
predicted to elicit locomotor hyperactivity as supported by past evidence from Bevins and 
Palmatier (2002) and that rats neonatally treated with quinpirole would show greater levels of 
hyperactivity as compared to controls.
3) Analyze sex differences in nicotine-conditioned hyperactivity in both D2-primed 
and non-D2-primed adolescent male and female rats. It was predicted that female rats would 
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demonstrate higher activity levels as a result of sensitization to nicotine in the conditioned-
hyperactivity paradigm. This hypothesis was supported by past evidence that has shown females 
demonstrate a more robust locomotor response to nicotine (Booze et al., 1999; Elliot et al., 2005; 
Faraday et al., 2003; Harrod et al., 2004; Kanyt et al., 1999; Perna, in press). This increased 
locomotor response would be further accentuated in D2-primed rats and greater activity will be 
observed in females versus males.
4) Analyze sex differences in the effects of dopamine D2 and D3 antagonists 
eticlopride and nafadotride, respectively, on nicotine-conditioned hyperactivity in both D2-
primed and non-D2-primed adolescent male and female rats. It was predicted that female rats 
would show higher levels of locomotor activity as compared to males in response to 
administration of dopamine D2 and D3 receptor antagonists. These hypotheses were based on 
results indicating increased dopamine D1 receptor sensitivity to the activating effects of D1 
receptor agonists and decreased sensitivity to activity depressing effects of D2 receptor agonists 
in female rats as compared to males (Schindler & Carmona, 2002). Inhibition of the D2 receptor 
would lead to a greater decrease in activity levels in male rats as compared to females. The 
expected result was that females would exhibit higher activity levels in response to the dopamine 
D3 receptor antagonist. This may possibly result from a decrease in D3-regulated inhibition of 
activity based on findings that female rats had fewer D3 receptors in the NAcc after repeated 
intravenous nicotine administration as compared to males (Harrod et al., 2004). 
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CHAPTER 2
METHODS
Subjects
Ninety-eight offspring of Sprague-Dawley rats ordered from Harlan, Inc. (Indianapolis, 
IN) were used in both experiments. The day of birth was counted as postnatal day zero (P0) and 
pups were weaned from the dam at P22. Animals were housed in a climate-controlled vivarium 
maintained on a 12 h light: 12 h dark cycle and food and water were available ad libitum. All 
procedures used in this study were in accordance with and approved by the East Tennessee State 
University Animal Care and Use Committee and the vivarium is fully accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Drug dosage
Animals were administered of 10 mg/kg of quinpirole based on findings by Kostrzewa et 
al. (1990) that this dose is sufficient to produce long-term priming of the dopamine D2 receptor. 
Nicotine bitartrate (Sigma-Aldrich, St. Louis, MO) was diluted in saline to 0.5 mg/kg free base 
(pH ~ 7.0). For Experiment 1, S-(-)-eticlopride hydrochloride (Sigma-Aldrich, St. Louis, MO) 
was diluted in saline to 0.1 mg/kg based on findings by Palmatier and Bevins (2002) that this 
dose is sufficient to impair locomotor activity in a nicotine conditioned hyperactivity paradigm. 
For Experiment 2, L-nafadotride (Sigma-Aldrich, St. Louis, MO) was diluted in saline to 0.1 
mg/kg based on findings by Murray and Bevins (2007) that this dose maintains specificity for the 
dopamine D3 receptor subtype.
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Drug Treatment
Neonatal. On postnatal days 1 to 21 (P1-P21), animals were given a single daily 
intraperitoneal (i.p.) injection of either quinpirole (10 mg/kg) or saline. Animals were randomly 
assigned to treatment group in order to maintain relative sameness in group size. All animals 
gained weight normally during drug treatment. 
Adolescent. Animals were randomly assigned to treatment groups on P28. Animals were 
drawn from 9 litters and were assigned to the following treatment group with the first drug 
representing neonatal treatment, the second representing the administered antagonist (or Saline if 
control group), and the third representing adolescent treatment: Saline-Saline-Saline (SSS), 
Saline-Saline-Nicotine (SSN), Quinpirole-Saline-Saline (QSS), Quinpirole-Saline-Nicotine 
(QSN)  Saline-Eticlopride-Saline (SES); Saline-Eticlopride-Nicotine (SEN) Quinpirole-
Eticlopride-Saline (QES), Quinpirole-Eticlopride-Nicotine (QEN), Saline-Nafadotride-Saline 
(SNS), Quinpirole-Nafadotride-Saline (QNS), Saline-Nafadotride-Nicotine (SNN), or 
Quinpirole-Nafadotride-Nicotine (QNN). Animals in the SS, QS, SES, QES, SNS, and QNS 
treatment groups served as the unpaired group (Bevins & Palmatier, 2003) which served as 
controls for the context-nicotine paired groups. The rationale for this group is that these animals 
received the same number of exposures to nicotine but did not have the drug paired within an 
environmental context. 
Apparatus
The two locomotor arenas were Plexiglas boxes painted black and measuring 72 cm on 
all sides. The identical locomotor arenas served as the conditioning contexts. According to 
classical conditioning, the locomotor arenas serve as the conditioned stimulus that elicits the 
conditioned response of horizontal locomotor activity after being reliably and repeatedly paired 
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with the unconditioned stimulus, nicotine. All activity was monitored by an automated 
behavioral scanning system (Any Maze, Stoelting Co., Wood Dale, IL). A grid was 
superimposed on the floor of the locomotor arena using the Any-Maze scanning system. Number 
of lines crossed served as the dependent variable of horizontal activity. Two locomotor arenas 
were used because the behavioral scanning system allowed for simultaneous data collection of 
two subjects.
Behavioral testing procedure
Beginning on P29, animals were habituated to the locomotor arena for 3 consecutive 
days. On each day of habituation, all animals were given an injection of saline and placed into 
the locomotor arena 10 minutes later. Each habituation session lasted for 10 minutes. This was 
done to allow animals to adapt to the locomotor apparatus and to the injection procedure. 
Beginning on P32, animals were injected i.p. with either nicotine (0.5 mg/kg free base) or saline. 
Animals were injected i.p. with either eticolopride (0.1 mg/kg), nafadotride (0.1 mg/kg), or 
saline 10 minutes before the nicotine or saline injection. Ten minutes after the adolescent 
treatment injection, the animals were placed into the locomotor arena for a 10-minute session. 
This procedure was repeated every other day for 18 days resulting in 9 days of sensitization 
testing. 
Animals in the unpaired groups (SSS, QSS, SES, QES, SNS, and QNS) were 
administered saline before being placed into the locomotor arena and nicotine in the home cages 
2 h after conditioning to control for nicotine exposure. The unpaired groups are so named 
because they receive the same number of exposures to nicotine; however, the drug is not 
repeatedly or reliably paired with the conditioned context. For the conditioned hyperactivity test, 
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all animals were given a saline injection and 10 minutes later were placed into the locomotor 
arena for one 10-minute session and behavior was recorded.
Research Design and Data Analysis
An initial 2 (sex) x 2 (neonatal drug treatment) x 2 (antagonist) x 2 (adolescent) x 5 
(repeated measure) five-way mixed factorial ANOVA was performed for both the eticlopride and 
nafadotride treated groups. There was a significant sex main effect in each experiment. 
Therefore, sex effects was analyzed separately using two 2 (neonatal) x 2 (antagonist) x 2 
(adolescent) x 9 (day of testing) ANOVAs. The Newman-Keuls post hoc test was used to 
analyze significant interactions. 
Planned comparisons were used to analyze conditioned hyperactivity data collected 
during the drug-free trial. These comparisons were made to answer the following specific 
questions. Group SSS was compared to group SSN to determine whether nicotine elicited 
conditioned-hyperactivity. Group SSN was compared to group SSN to determine the effect, if 
any, of D2-priming on conditioned-hyperactivity. Group SEN was compared to group SSN to 
examine the effect of eticlopride on conditioned hyperactivity. Finally, Group QEN was 
compared group QSN to examine the effect of eticlopride on conditioned-hyperactivity in D2-
primed rats. The four planned group comparisons for conditioned hyperactivity were the same 
for both males and female rats.  
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CHAPTER 3
RESULTS
Sex Differences in Nicotine Sensitization for Rats Administered Eticlopride
Initial analyses. Although there were several significant main effects and interactions, the 
initial analysis focused on analyzing sex differences and their interaction with drug treatment. 
The initial 2 x 2 x 2 x 2 x 9-way ANOVA of sex, neonatal, antagonist (eticlopride or saline), 
adolescent, and day of testing yielded a significant main effect of sex F(1,94) = 10.11, p<.002,  
significant two-way interactions of Sex x Antagonist F(1,94) = 3.68, p<.05, Sex x Day of Testing 
F(8,752) = 2.01, p<.04, a significant three-way interaction of Sex x Neonatal Drug Treatment  x 
Day of Testing F(8,752) = 2.30, p<.04 and Sex x Antagonist x Day of Testing F(8,752)  1.98, 
p<.04. 
Analysis of the significant sex main effect revealed that overall females were 
significantly more active than males. Post hoc analysis of the significant interactions with the 
Newman-Keuls test revealed that females administered saline in the absence of an antagonist 
demonstrated significantly higher levels of activity than males administered saline, but females 
and males were equivalent in their horizontal activity when administered eticlopride. Females 
demonstrated higher levels of horizontal activity as compared to males on days 1-3 and 7-8. In 
particular, females neonatally administered saline demonstrated higher levels of horizontal 
activity as compared to males on days 4 and 8, and females administered saline demonstrated 
significantly higher levels of horizontal activity a compared to males administered saline or 
eticlopride on days 3-5 and 7-9. In summary, adolescent females demonstrated significantly 
higher levels of horizontal activity than adolescent males, an effect that has been repeatedly 
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observed in the research literature (Becker, 1999; Booze et al., 1999; Elliot et al., 2005; Faraday 
et al., 2003; Harrod et al., 2004; Kanyt et al., 1999; Perna, 2006). 
Horizontal Activity for Male Rats Administered Eticlopride. A 2 x 2 x 2 x 9  four-way 
repeated measures ANOVA revealed a significant main effect of Antagonist F(1,47) = 50.99, 
p<.001, significant two-way interactions of Antagonist x Adolescent Drug Treatment F(1,47) = 
5.25, p<.027, Neonatal Drug Treatment x Day of Testing F(8,376) = 2.67, p<.007, Antagonist x 
Day of Testing F(8,376) = 15.80, p<.001, Adolescent Drug Treatment x Day of Testing F(8,376) 
= 7.72, p<.001, and significant three-way interactions of Neonatal Drug Treatment x Antagonist 
x Day of Testing F(8,376) = 2.12, p<.033, and Adolescent Drug Treatment x Antagonist x Day 
of Testing F(8,376) = 3.56, p<.001. Finally, a significant four-way interaction of Neonatal Drug 
Treatment x Antagonist x Adolescent Drug Treatment x Day of Testing F(8,376) = 2.94, p<.02. 
Most importantly, this interaction revealed that Male Group QSN demonstrated significantly 
higher levels of horizontal activity than all other groups at days 7 through 9.  Also, Male Group 
SSN demonstrated significantly higher levels of horizontal activity than Group SSS at days 7 
through 9 demonstrating sensitization in this group. Results of this analysis are shown in Figure 
1.
Figure 1. Horizontal Activity for Males Administered Eticlopride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
37
Figure 1. Horizontal Activity for Males Administered Eticlopride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
Horizontal Activity for Female Rats Administered Eticlopride. A 2 x 2 x 2 x 9 four-way 
ANOVA revealed significant main effect of Antagonist F(1,49) = 126.67, p<.001, significant 
two-way interactions of Antagonist x Adolescent Drug Treatment F(1,49) = 7.89, p<.007, 
Neonatal Drug Treatment x Day of Testing F(8,392) = 2.73, p<.006, and Antagonist x Day of 
Testing F(8,392) = 9.51, p<.001, two significant three-way interactions of Antagonist x 
Adolescent Drug Treatment x Day of Testing F(8,392) = 3.69, p<.001, and Neonatal Drug 
Treatment x Adolescent Drug Treatment x Day of Testing F(8,392) = 2.14, p<.03. Results of this 
analysis are shown in Figure 2.
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 First, the significant main effect of Antagonist demonstrated that eticlopride resulted in 
lower levels of horizontal activity compared to all other groups. Post hoc analysis of the two-way 
interactions revealed that animals administered nicotine or saline in adolescence demonstrated 
significantly higher levels of horizontal activity compared to animals administered eticlopride or 
saline. Females neonatally treated with saline demonstrated significantly higher levels of 
horizontal activity at days 4 and 8. Females administered eticlopride demonstrated significantly 
lower levels of horizontal activity from days 2 through 9. 
Analysis of the three-way interaction of Antagonist x Adolescent Drug Treatment x Day 
of Testing revealed that eticlopride effectively produced a significant decrease of horizontal 
activity in females administered nicotine in adolescence as compared to animals administered 
eticlopride plus saline during at days 3 and 6 through 9. Females neonatally administered saline 
and given saline, as opposed to an antagonist, and nicotine in adolescence (Group SSN) had 
significantly higher levels of horizontal activity at days 6 through 8. Interestingly, Group SSN 
activity levels drop to control levels on day 9. 
Finally, and most importantly, analysis of the significant three-way interaction of 
Neonatal Drug Treatment x Adolescent Drug Treatment x Day of Testing revealed that females
administered saline neonatally and nicotine in adolescence demonstrated significantly higher 
levels of horizontal activity at days 5 through 8 than all other groups. Additionally, females 
administered quinpirole neonatally and nicotine in adolescence (Group QSN) were equivalent to 
the control group of females administered saline neonatally during antagonism and in 
adolescence (Group SSS). This effect replicates past work in adolescence that has shown that 
D2-primed females administered nicotine appear to decrease horizontal activity due to increases 
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in stereotypic behaviors, such as grooming, paw treading, and vacuous chewing movements late 
in nicotine sensitization testing (Perna, 2006). 
Figure 2. Horizontal Activity for Females Administered Eticlopride 
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
Sex Differences in Nicotine-Conditioned Hyperactivity for Rats Administered Eticlopride
Conditioned Hyperactivity for Male Rats Administered Eticlopride. There were four 
planned group comparisons performed for conditioned hyperactivity in males: Groups SSN to 
SSS, SSN to QSN, SEN to SSN, QEN to QSN, and SEN to SSN (see Figure 3). For the planned 
group comparison of Group SSN to SSS, the independent t-test was not significant t(12) = .41, 
p=.69, demonstrating that nicotine did not produce conditioned hyperactivity in adolescent 
males. However, the planned comparison of Group SSN to QSN, was significant t(12) = 2.63, 
p<.022, and Group QSN demonstrated a significant increase in horizontal activity as compared 
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to Group SSN. The planned comparisons of SEN to SSS t(11) = .65, p=.53 and QEN to QSN 
were also not significant t(12) = .92, p=.38. 
Figure 3. Conditioned Hyperactivity for Males Administered Eticlopride
Conditioned Hyperactivity for Female Rats in Administered Eticlopride. The same four 
planned group comparisons performed for males were also performed to examine conditioned 
hyperactivity in females: Groups SSN to SSS, SSN to QSN, SEN to SSN, and QEN to QSN (see 
Figure 4).  For the planned group comparison of Group SSN to SSS, the independent t-test was 
significant t(10) = 3.54, p<.006. Group SSN demonstrated a significant higher level of activity 
on the drug free test than Group SSS. Likewise, Group SSN demonstrated significantly higher 
levels of activity on the drug free test than Group QSN t(9) = 2.59, p<.03. The planned 
comparison of Groups QEN and QSN was not statistically significant t(12) = .27, p=.78. The 
planned comparisons of Group SSN to SEN revealed another significant effect t(12) = 2.27, 
p<.04. 
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Figure 4: Conditioned Hyperactivity for Females Administered Eticlopride 
Sex Differences in Nicotine Sensitization for Rats Administered Nafadotride.
Initial Analyses.  Similar to the analysis of rats administered eticlopride, there were 
several significant main effects and interactions, but in this initial analysis we were primarily 
interested in analyzing sex differences and their interaction with drug treatment. An initial nine-
way ANOVA with sex, neonatal, antagonist, adolescent, and day of testing (2 x 2 x 2 x 2 x 9) 
yielded a significant main effect of sex F(1,77) = 7.43, p<.008,  significant two-way interactions 
of Sex x Antagonist F(1,94) = 3.68, p<.05, Sex x Day of Testing F(8,616) = 3.22, p<.001. Two 
significant four-way interactions of Sex x Neonatal Drug Treatment x Antagonist x Day of 
Testing F(8,616) = 3.0, p<.002 and Sex x Antagonist x Adolescent Drug Treatment x Day of 
Testing.
The analyses of the first of these two higher order interactions revealed increased 
horizontal activity in females administered saline as opposed to the D3 antagonist nafadotride at 
days 4, 5, 8, and 9. There were no significant group differences in males. The analysis of the 
latter of these two higher order interactions revealed that females neonatally treated with saline 
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and administered nicotine during adolescent treatment demonstrated significantly higher levels 
of horizontal activity than all other groups at days 5 through 9, and this effect was blocked by 
nafadotride. Males neonatally administered saline and given nicotine in adolescence also 
demonstrated a significant increase in horizontal activity at days 6, 8, and 9 as compared males 
given saline at both time points. Again, this effect was blocked by nafadotride. Based on these 
sex differences, males and females were analyzed separately.
Horizontal Activity for Male Rats Administered Nafadotride.  A 2 x 2 x 2 x 9 four-way 
ANOVA revealed no significant main effects. There significant two-way interactions of 
Antagonist x Adolescent Drug Treatment F(1,45) = 7.37, p<.009, Antagonist x Day of Testing 
F(8,360) = 3.19, p<.002, and Adolescent Drug Treatment x Day of Testing F(8,360) = 8.06, 
p<.001. There was a significant three-way interaction of Neonatal Drug Treatment x Antagonist
x Day of Testing F(8,360) = 3.50, p<.001. Finally, there was a significant four-way interaction of 
Neonatal Drug Treatment x Antagonist x Adolescent Drug Treatment x Day of Testing F(8,360) 
= 2.01, p<.04. Results of this analysis are shown in Figure 5.
Post hoc analysis of the most complex interaction revealed that Group QSN had 
significantly higher levels of horizontal activity on Days 7 through 9 compared to all other 
groups. Group QNN demonstrated a significant increase in horizontal activity compared to 
Group QSN on day 1 but was equivalent to controls, Group SSS, throughout testing. This result 
demonstrates that nafadotride blocked locomotor sensitization to nicotine in D2-primed males
and also blocked the initial hypoactive response to nicotine. However, in non D2-primed males
nafadotride blocked locomotor sensitization to nicotine but, interestingly, produced an initial 
hypoactive response in Group SNN as compared to Group SSN at day 1. 
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Figure 5. Horizontal Activity for Males Administered Nafadotride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
$ indicates Group QNN was significantly greater than Group QSN on Day 1
Horizontal Activity for Female Rats Administered Nafadotride. A 2 x 2 x 2 x 9 four-way 
ANOVA revealed a significant main effect of Antagonist F(1,39) = 7.94, p<.008, a significant 
two-way interaction of Adolescent Drug Treatment x Day of Testing F(8,312) = 7.66, p<.001, a 
significant three-way interactions of Antagonist x Adolescent Drug Treatment x Day of Testing 
F(8,312) = 2.93, p<.003, and a significant four-way interaction of Neonatal Drug Treatment x 
Antagonist x Adolescent Drug Treatment x Day of Testing F(8,312) = 2.14, p<.04. These results 
are shown in Figure 6.
Most importantly, analysis of this four-way interaction revealed that Group SSN 
demonstrated significantly higher levels of horizontal activity at days 5 through 8. Group QNN 
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activity levels were equivalent to controls, Group SSS, at days 2 through 9. Groups QNN and 
SNN, nafadotride groups that received nicotine, demonstrated significant hypoactivity on day 1 
compared to control Group SSS. Interestingly, nafadotride blocked sensitization to nicotine; it 
did not block the initial hypoactive response to nicotine on day 1. Female Group QSN 
demonstrated significantly lower levels of horizontal activity as compared to Group SSN at days 
5 through 8, presumably due to increased stereotypy in this group.
Figure 6. Horizontal Activity for Females Administered Nafadotride
** indicates significance greater than all other groups (p < .05)
* indicates significance greater than control group SSS (p < .05)
$ indicates Group QNN demonstrated significantly lower activity levels as compared to Group 
SSS on Day 1
45
Sex Differences in Nicotine-Conditioned Hyperactivity for Rats Administered Nafadotride
Conditioned-Hyperactivity for Male Rats Administered Nafadotride. Only two planned 
comparisons were performed on conditioned hyperactivity: The comparison of Groups SNN to 
SSN was made to examine if nafadotride blocked conditioned hyperactivity.  The comparison of 
Group QNN to QSN was performed to examine the effect of nafadotride on nicotine-conditioned 
hyperactivity in D2-primed rats. The comparison of Groups SNN to SSN was not statistically 
significant t(8) = .044, p=.96. In the comparison of QNN to QSN, the t-test was statistically 
significant t(10) = 2.97, p<.01. Group QSN demonstrated significantly higher levels of 
horizontal activity compared to Group QNN, demonstrating that nafadotride blocked nicotine 
conditioned hyperactivity in adolescent males. These results are shown in Figure 7. 
Figure 7. Conditioned Hyperactivity for Males Administered Nafadotride
Conditioned-Hyperactivity for Female Rats Administered Nafadotride. Similar to males, 
only two planned comparisons were performed on conditioned hyperactivity. The first 
comparison of QNN to QSN was designed to test whether D2-priming effects on nicotine 
conditioned increases in locomotor activity were blocked by nafadotride. The second comparison 
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of Groups SNN to SSN was designed to test whether nafadotride blocked nicotine conditioned 
increases in locomotor activity in non D2-primed female adolescent rats. The planned 
comparison of Group QNN to QSN was not significant t(12) = 1.34, p=.21. However, the 
planned comparison of Groups SNN to SSN was significant t(9) = 3.09, p<.013. The results of 
this analysis are shown in Figure 8.
Figure 8. Conditioned Hyperactivity for Females Administered Nafadotride
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CHAPTER 4
DISCUSSION
The results of the present study support previous findings that priming of the dopamine 
D2 receptor results in enhanced behavioral sensitization to nicotine (Perna, 2006). In addition, 
this study also demonstrated that antagonizing the D2 and D3 receptor subtype blocks this 
sensitization suggesting differential roles of dopamine receptor subtypes in the induction of 
nicotine sensitization. Antagonism of the D2 receptor blocked nicotine-conditioned hyperactivity 
in female rats but not male rats. Nafadotride blocked nicotine-conditioned hyperactivity in D2-
primed male rats but not female rats. These results suggest sex-based differential roles of the D2 
and D3 receptor subtypes on the association of nicotine with conditioned contextual cues.
Nicotine Sensitization 
D2 priming blocked the initial hypoactive behavioral response typically observed after 
administration of nicotine (Brown & Kolb, 2001). This result is in agreement with previous 
findings that adolescent rats also showed less sensitivity to nicotine’s initial hypoactivity effects 
(Elliot et al., 2005). Overall, D2 primed rats that received nicotine demonstrated a significant
increase in activity compared to other groups and reached the asymptote of locomotor response 
to nicotine more rapidly as compared to controls. Results showed that in male rats D2 priming 
enhanced sensitization to nicotine as compared to non D2-primed rats. In female D2-primed rats 
administered nicotine demonstrated an increased hypoactive response after initial sensitization. 
The quantitative decrease in horizontal activity after initial sensitization is hypothesized to result 
from qualitatively observed increases in stereotypic behaviors such as sniffing, licking, 
grooming, and rearing movements (Kelley, 2001; Lepekhina, & Tsitsurina, 2007). These 
observations are in agreement with previous findings that female rats show increased periods of 
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stereotypic behavior after administration of the psychostimulants amphetamine (Milesi-Halle, 
McMillan, Laurenzana, Byrnes-Blake, & Ownes, 2007) and nicotine (Perna, 2006). 
Another factor that may lead to increased stereotypic behavior in female rats is increased 
dopamine D1 receptor sensitivity as compared to male rats (Schindler & Carmona, 2002). 
Vezina and Stewart (1989) posit that the D1 receptor subtype plays a more important role in 
locomotor sensitization to psychostimulants as compared to the D2 receptor subtype. However, 
knockout studies have shown that D2 receptor mutants demonstrate more drastic reductions in 
motor function as compared to D1 receptor mutants (Kobayashi et al., 2004). Reductions in 
locomotor activity in D1 mutants are dependent upon the experimental protocol used suggesting 
an important interrelationship between receptor subtypes in the control of motor activity 
(Kobayashi et al.). However, differential findings of the importance of the D1 versus D2 receptor 
in locomotor sensitization may reflect species specific differences in receptors.  
Nicotine induced dopamine release in the nucleus accumbens, striatum, and to some 
extent the frontal cortex, is modulated by presynaptic nicotinic acetylcholinergic receptors 
(nAChRs) on dopaminergic terminals of neurons in the nucleus accumbens (Grady, Marks, 
Wonnacott, & Collins, 1992; Marshall, Redfern, & Wonnacott, 1997). Nicotine also blocks the 
inhibitory action of dopamine at the presynaptic D2 autoreceptor resulting in additional synaptic 
availability of dopamine (Barik & Wonnacott, 2006). Increased receptor sensitivity combined 
with increased neurotransmitter availability may, in part, account for the augmented behavioral 
sensitization and sex differences in behavior observed in the present study.
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Antagonism of Dopamine Receptor Subtypes 
D2 Receptor. In agreement with Bevins and Palmatier (2002), eticlopride blocked 
induction of nicotine sensitization in male and female rats. Interestingly, eticlopride was more 
effective at blocking sensitization to nicotine in D2-primed as compared to non D2-primed rats 
which is presumably due to increased sensitivity of the D2 receptor as a result of neonatal 
receptor priming (Kostrzewa, 1995), and eticlopride is binding more effectively to primed D2 
receptors.
D3 Receptor. Inconsistent with findings by Murray and Bevins (2007), the D3 antagonist 
nafadotride blocked sensitization in both D2-primed and non D2-primed male and female rats.
This result is also inconsistent with previous findings that nafadotride failed to block expression 
of sensitization to the psychostimulant cocaine (Betancur et al., 2001; Filip, Papla, & Czepeil, 
2002) but is consistent with past work with amphetamine (Chiang, Chen, & Chen, 2003; 
Richtand et al., 2000). This may be a spurious result, but it may also be that the present results 
reflect age differences in dopamine D3 receptor function, as all of these past studies have used 
adults as subjects.  
Adolescent D3 receptor levels have been shown to be at only 40% of adult levels during 
the adolescent period (Faraday et al. 2003; Shram et al., 2006).  Thus, it may be that these 
receptors increase sensitivity due to their low number in the brain and play a larger role in 
locomotor sensitization to nicotine in adolescence than in adulthood. On the other hand, it may 
be that adolescent animals are more likely to demonstrate increases in stereotypic behaviors, as 
observed in the present study in nicotine given to D2-primed females. Thus horizontal activity 
may not be the most accurate behavioral measure for activation to psychostimulant drugs.  One 
important consistency however is that nafadotride fails to block sensitization to amphetamine 
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(Chiang et al., 2003). Both amphetamine (Nowak, Brus, & Kostrzewa, 2001) and nicotine 
(Benowitz, 2008) produce an increase in dopamine release and block the presynaptic dopamine 
D2 receptor autoreceptor (Geldwert et al., 2006). Nicotine and amphetamine may have similar 
actions at the synapse and these actions may be blocked by D3 antagonism.  Further studies are 
needed to examine sex differences in D3 receptor density and the possible effects of density on 
the associative conditioning properties of nicotine.
Dopamine Receptor Density in Adolescence. Andersen and Teicher (2000) have shown 
sex differences in dopamine receptor density over the periadolescent period, which has been 
defined as occurring from approximately P28 to P60 (Smith, 2003), as compared to the adult 
period.  Dopamine D2 receptor density in the striatum of male rats increases 1.4 fold between 
P25 and P40, whereas D2 receptor density in the striatum of female rats is increased by only 
31% during this time. Male D2 receptor density sharply decreases by 55% by adulthood, whereas 
females show little overproduction during the same developmental period. Interestingly, during 
adulthood, there were no sex differences in the density of D1 and D2 receptors (Andersen & 
Teicher).
The results of this study support previous findings that adolescent rats, particularly D2-
primed adolescents, demonstrated a more robust sensitization to nicotine as compared to adult 
rats (Elliot et al., 2005; Perna, 2006), based on the increases in dopamine receptor density during 
the adolescent period. Further, these increases in dopamine receptor density suggest that drugs 
enhancing the dopaminergic system, such as addictive drugs, may have more prevalent effects 
during this period. Certainly, the results shown here support this effect in males, as D2-primed 
males demonstrated an enhanced sensitization to nicotine, suggesting increased behavioral 
activation to nicotine. 
51
Alternative Mechanisms. Several studies have shown that multiple neurotransmitters 
systems are affected by nicotine including the cholinergic (Brown et al, 2006; Quarta et al., 
2007), glutamatergic (Balfour et al., 1996; Birrell & Balfour, 1998; Domino, 2001; Shoaib et al., 
1994; Suemaru et al., 1993), and GABAergic systems (Carlsson, 2000). Blockade of nicotinic or
glutamatergic receptors has been shown to block sensitization to nicotine, suggesting that the 
cholinergic or glutamatergic systems may also play a role in sensitization to nicotine. 
Nicotinic receptors are located both pre- and postsynaptically, and the presynaptic 
nicotinic receptor has been shown to be located on cholinergic, glutamatergic, serotinergic, as 
well as dopaminergic neurons (McKay, Placzek, & Dani, 2007).  This ubiquity of the nicotinic 
receptor throughout the brain makes the action of nicotine difficult to understand. Certainly, had 
an antagonist to another neurotransmitter system been used in the present study, it very well may 
have blocked sensitization to nicotine, and it is realized that the mechanism underlying the 
behavioral results observed in the present study may be mediated by several neurotransmitter 
systems.  Regardless, current evidence still supports increased dopamine release in the nucleus 
accumbens via the direct agonist actions of nicotinic receptors located in the VTA (Di Chiara et 
al., 2004; Perna, 2006; Shim et al., 2001; Shoaib et al., 2004).
Nicotine-Conditioned Hyperactivity
Results suggest that D2 priming enhanced conditioned hyperactivity to nicotine in males,
and this effect was not blocked by the D2 antagonist eticlopride. Further, non D2-primed males 
administered nicotine did not demonstrate conditioned hyperactivity. Results showed that 
eticlopride, a dopamine D2 antagonist, blocked conditioned hyperactivity in females but not in 
males, suggesting that the D2 receptor plays a role in the association of nicotine with a 
conditioned context, at least in females. This is somewhat consistent with past research. 
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Schindler and Carmona (2002) have shown that adult female rats demonstrate an increase in 
locomotor activation to acute quinpirole. The result that females administered eticlopride failed 
to demonstrate nicotine conditioned hyperactivity further supports results showing there are sex 
differences in D2 receptor function, especially in adolescence. 
The results using the dopamine D3 antagonist nafadotride were more complex. First, 
nafadotride blocked conditioned hyperactivity in non D2-primed females. This result, taken with 
the findings with the D2 antagonist eticlopride, suggests that both the D2 and D3 receptor play a 
role in the conditioned effects of nicotine in females. Further, because D2-primed females did 
not demonstrate conditioned hyperactivity to nicotine, it does not appear that priming of the D2 
receptor in females affects associative effects of nicotine as it relates to behavioral activation. 
Nafadotride was effective in blocking conditioned hyperactivity in D2-primed males, but 
because non D2-primed males did not demonstrate nicotine conditioned hyperactivity, it did not 
produce any effects in this group. Thus, the D3 receptor may play a more important role in 
expression of behavioral activation to nicotine in males as compared to females; however, there 
is a reasonable alternative explanation. 
To produce priming of the dopamine D2 receptor, ontogenetic quinpirole was 
administered. Quinpirole is a dopamine D2/D3 agonist, thus, both D2 and D3 receptors may be 
primed. Further, work by Collins et al. (2005) has shown that the D3 receptor is more important 
in yawning behavior as compared to the D2. All of this taken together suggests that the D3 
receptor may also be primed in these animals and may be playing a more important role in 
nicotine association in males as compared to the D2 receptor. Increased sensitivity of the D3 
receptor, which has been shown to play an important role in the association of nicotine with a 
conditioned context (Le Foll et al., 2005), may have resulted in increased behavioral response to 
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the conditioned context during the drug-free trial. This is especially interesting considering the 
importance of the dopamine system in addiction to nicotine, and sex differences that have been 
shown in not only schizophrenics (Leung & Chue, 2000) but in the normal population (Bigos et 
al., 2008).    
Initially, the finding that non-D2-primed females exhibited a significantly higher 
conditioned hyperactivity response as compared to D2-primed females and controls is surprising. 
However, previous studies by Harrod et al. (2004) have shown decreased numbers of D3 
receptors in the NAcc in female rats as compared to males after repeated intravenous nicotine 
administration. The reduction in supersensitized D3 receptors in the accumbens shell of D2-
primed female rats as a result of chronic nicotine administration may partially account for this 
finding. 
The importance of the D3 receptor in association of drugs of abuse with contextual 
stimuli may be due to the increased number of receptors in the accumbens shell as compared to 
the core (Stanwood, McElligot, Lu, & McGonigle, 1997). As previously mentioned, the shell of 
the nucleus accumbens (AccSh) has been proposed as a histological extension of the amygdala, 
the emotional center of the brain that is thought to play an important role in associative learning 
in rewarding situations (Everitt, Morris, O’Brien, & Robbins, 1991; Meredith, Callen, & 
Scheuer, 2002). Therefore, it is not surprising that administration of the D3 antagonist more 
effectively blocked nicotine-conditioned hyperactivity as compared to the D2 antagonist 
eticlopride.
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Clinical Relevance
 The findings of the current studies present several considerations for the treatment of 
nicotine addiction, particularly in the schizophrenic population. The apparent importance of the 
D2 receptor in nicotine sensitization suggests that treatments targeting the D2 receptor may be 
useful for simultaneous cessation of smoking and treatment of the positive symptoms of 
schizophrenia as it appears. The increased sensitivity of D2-primed rats to nicotine exposure 
provides additional support for D2-priming as an animal model of schizophrenia. This result is 
consistent with human schizophrenia literature focused on nicotine addiction in this group (Salin-
Pascual, Alcocer-Castillejos, & Alejo-Galarza, 2003). Bigos et al. (2008) have recently shown 
that smoking impacts the metabolism of and may therefore reduce the effectiveness of 
olanzapine in the treatment of schizophrenia. Therefore, drug interactions must always be 
considered when developing new treatments. 
As noted by Le Foll et al. (2007), the D3 receptor represents another potential target for 
the treatment of nicotine addiction. Findings from this study support the role of D3 receptors in 
the association of nicotine to conditioned stimuli as evidenced by the blockade of nicotine-
conditioned hyperactivity during the drug-free trial. Targeting the D3 receptor may be especially 
beneficial for male schizophrenic patients indicated by the result that D2-primed male rats 
showed the highest levels of conditioned hyperactivity. The D3 receptor provides a potential 
target for treatment of cravings associated with stimuli associated with smoking. Perhaps 
development of a pharmacological agent that antagonizes both the D2 and D3 receptor will aid in 
the reduction of nicotine addiction by relieving both the physical and associative addiction to 
nicotine that smokers suffer. 
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Conclusion
The aim of this investigation was to determine the effect of a nicotine-conditioned 
context on locomotor hyperactivity in an animal model of D2-priming, and whether conditioned 
hyperactivity could be blocked by the D2 antagonist eticlopride or the D3 antagonist nafadotride.
The results of this study demonstrate that the D2 and D3 dopamine receptor subtypes are 
important in both the locomotor activating effects of nicotine and also the association of nicotine 
with conditioned stimuli, particularly environmental cues. More specifically, results 
demonstrated that a nicotine-conditioned context can elicit hyperactivity and that hyperactivity is 
blocked by both D2 and D3 receptor antagonism in female rats and D3 receptor antagonism in 
male rats. These results also demonstrate differences in locomotor activity levels of D2-primed 
and non D2-primed rats suggesting that nicotine will also have different effects in schizophrenic 
patients as compared to the general population. 
These results support previous findings that demonstrate the existence of sex differences 
in locomotor sensitization and hyperactivity that may result from differences in receptor 
sensitivity or density (Harrod et al., 2004; Le Foll, Diaz, et al., 2003; Schindler & Carmona, 
2002) during different developmental periods. Sex differences in receptor subtype density during 
adolescence, receptor sensitivity throughout development, and the introduction of differential 
hormone levels at sexual maturity are all factors that impact nicotine’s effects on behavior. This 
study highlights the need for additional research in sex differences, age differences, and the 
importance of these two factors in the development of new treatments for nicotine addiction not 
only in schizophrenia, but also the general population.
It is also important to point out that all antipsychotics used to treat schizophrenia block 
the dopamine D2 receptor with some affinity. The results of this study demonstrate that the D2 
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and D3 receptor are involved in both the physiological and psychological aspects of nicotine 
addiction. The applications of these findings are very important relative to the interaction of 
pharmacological treatment and typical nicotine abuse in the schizophrenic population. Therapies 
should focus not only on pharmacologically treating the psychological addiction to nicotine but 
also the psychological addiction triggered by environmental cues. 
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